IQVIA

Market Access

Nine for 2023, part three: thriving or surviving?

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry

Patients

Nine for 2023, part two: healthcare’s hard problem, the prog...

The first part of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year,

Views & Analysis

Bringing the Benefits of eCOA BYOD Strategies to Clinical St...

Over the past few years, many clinical study administrators wanted to use the bring your own device (BYOD) model within their eCOA, but they were typically constrained by regulatory require

Patients

Talent across borders: opening doors for refugee pharmacists...

The idea of rebuilding your life from scratch, far away from the people, culture, and places you know and love, would be challenging for many people.

Views & Analysis

It’s time get real with healthcare's commitment to net zero

Every fraction of a degree matters

News

IQVIA's report card for clinical trial diversity: must do be...

The lack of diversity in clinical trials has been a topic of debate for decades, but was thrust into the spotlight as the impact of the pandemic on poorer, less educated, and ethnically div